Cogent Biosciences, Inc. Proceeds from Divestiture of Businesses
Cogent Biosciences, Inc. (COGT) reported Proceeds from Divestiture of Businesses of $8.10 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2022-03-15
- Cogent Biosciences, Inc. proceeds from divestiture of businesses for the quarter ending 2020-12-31 was $0.00.
- Cogent Biosciences, Inc. proceeds from divestiture of businesses for fiscal 2020 was $8.10M.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $8.10M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $8.10M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |